Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine launches the BLOOM Phase 3 PPD study of LPCN 1154 and says existing cash should cover the trial’s planned execution.

Rhea-AI Summary

Lipocine (LPCN) has initiated BLOOM, a Phase 3 outpatient study of oral brexanolone candidate LPCN 1154 for severe postpartum depression, with first participant dosing expected in early Q4 2026.

The trial plans to enroll approximately 120 participants and is designed to support a potential New Drug Application under the 505(b)(2) pathway. BLOOM incorporates U.S. FDA feedback and learnings from a prior Phase 3 study that did not meet its primary endpoint but, in post hoc analyses excluding one anomalous high-enrolling site, suggested rapid and sustained symptom improvement; these findings are described as exploratory and non-confirmatory. The earlier trial reported no treatment-related severe or serious adverse events and no excessive sedation, loss of consciousness, or treatment discontinuations.

Lipocine expects its existing resources to fund BLOOM, with projected average cash use of about $1 million per month and $23.3 million in unrestricted cash, cash equivalents and marketable investment securities as of June 30, 2026.

Positive

• BLOOM Phase 3 study initiated for LPCN 1154 in severe postpartum depression, targeting potential 505(b)(2) NDA support
• Planned enrollment ~120 participants in a placebo-controlled outpatient design incorporating FDA feedback
• Prior Phase 3 safety showed no treatment-related severe/serious adverse events or treatment discontinuations
• Cash position $23.3 million unrestricted as of June 30, 2026
• Estimated cash use ~$1 million per month during BLOOM, and company expects existing resources to execute the study

Negative

• Prior Phase 3 trial of LPCN 1154 did not meet its primary endpoint in the full analysis set
• Exploratory efficacy signals rely on post hoc analyses excluding one anomalous site and are not confirmatory evidence
• Limited cash runway detail: expectations that existing resources fund BLOOM do not extend to approval or commercialization

News Explained

Lipocine says its existing resources can execute BLOOM, but that expectation depends on study duration, enrollment, costs and other operating needs and does not extend to regulatory approval or commercialization.

Market Context

On Jan 20, 2026, the prior LPCN 1154 Phase 3 enrollment announcement was followed by a -10.87% 24-ho...

Analysis

On Jan 20, 2026, the prior LPCN 1154 Phase 3 enrollment announcement was followed by a -10.87% 24-hour move; BLOOM now re-tests the same program after that trial missed its primary endpoint.

Key Figures

Planned participants: Approximately 120 participants First participant dosing: Early Q4 2026 Treatment duration: 48-hour +5 more

Planned participants

Approximately 120 participants

BLOOM Phase 3 study in severe postpartum depression

First participant dosing

Early Q4 2026

BLOOM Phase 3 study

Treatment duration

48-hour

Planned at-home oral treatment regimen

Regulatory pathway

505(b)(2) pathway

Potential New Drug Application

Prior primary endpoint

Not met

Prior Phase 3 trial in the full analysis set

Undetectable study drug

Approximately 40%

LPCN 1154-treated participants at one high-enrolling site

Treatment-related severe or serious adverse events

None reported

Prior Phase 3 trial

Average cash use

Approximately $1 million per month

During study execution, including BLOOM-related expenditures

Previous Clinical trial Reports

3 past events · Latest: Feb 18

Same Type 3 events

1. Feb 18

   Phase 3 completion

   24h Move

   -1.3%

   Prior LPCN 1154 Phase 3 trial reached last patient last visit with efficacy pending

2. Jan 20

   Phase 3 enrollment

   24h Move

   -10.9%

   Prior LPCN 1154 Phase 3 trial completed enrollment and dosing in severe PPD

3. Feb 18

   Phase 3 safety

   24h Move

   -1.3%

   Prior trial reported no drug-related serious adverse events or treatment discontinuations

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

505(b)(2) pathway, placebo-controlled, post hoc analyses, primary endpoint, +1 more

5 terms

505(b)(2) pathway regulatory

"support a potential New Drug Application under the 505(b)(2) pathway"

A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.

placebo-controlled medical

"The placebo-controlled outpatient study incorporates feedback"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

post hoc analyses medical

"exploratory post hoc analyses identified anomalies"

Analyses performed after the main study results are known to explore patterns or generate new ideas rather than to test a predefined hypothesis. Like looking back over a travel route to spot interesting detours, these checks can suggest additional benefits or risks but are more likely to be misleading and need confirmation in new, planned studies. Investors should treat post hoc findings as tentative signals that can influence expectations but carry higher uncertainty and regulatory scrutiny.

primary endpoint medical

"did not meet its primary endpoint in the full analysis set"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

full analysis set medical

"did not meet its primary endpoint in the full analysis set"

The full analysis set is the group of clinical trial participants whose data are included in the main effectiveness analyses — typically everyone who was enrolled, received treatment, and provided at least some follow-up data. For investors, this matters because the size and composition of that group affect how credible and representative the reported results are; it’s like judging a product by reading all customer reviews rather than a few selected ones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial
• Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026
• Company expects existing resources to support BLOOM

SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 (oral brexanolone) for PPD. First participant dosing is expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home treatment, targeting the need for rapid symptom relief with a short oral regimen. Lipocine believes this potential profile could address a substantial unmet need in PPD and represents an important commercial opportunity, subject to successful development and approval.

BLOOM is designed to complement the existing LPCN 1154 clinical data package and generate prospective efficacy and safety evidence to support a potential New Drug Application under the 505(b)(2) pathway. The placebo-controlled outpatient study incorporates feedback from a recent meeting with the U.S. Food and Drug Administration (FDA), together with learnings from the prior Phase 3 trial.

Although the prior Phase 3 trial did not meet its primary endpoint in the full analysis set, exploratory post hoc analyses identified anomalies concentrated at one high-enrolling site, including an absence of detectable study drug in blood samples from approximately 40% of LPCN 1154-treated participants at that site. Analyses excluding the site suggested rapid and sustained improvement in depressive symptoms. These findings are exploratory and are not confirmatory evidence of efficacy. BLOOM is designed to evaluate LPCN 1154 prospectively with strengthened site and data-quality controls.

The prior trial also provided encouraging safety and tolerability findings. No treatment-related severe or serious adverse events were reported, and there were no instances of excessive sedation, loss of consciousness or treatment discontinuation.

"We believe a treatment that delivers rapid relief through a 48-hour oral course at home could meaningfully change how women and families manage postpartum depression," said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. "BLOOM translates our prior clinical findings and FDA feedback into a study focused on generating the evidence needed to advance LPCN 1154 toward a potential regulatory submission. Our priorities are rigorous execution, clinically meaningful results and disciplined use of capital as we pursue this opportunity for patients and shareholders."

Based on its current operating plan, Lipocine believes its existing financial and operational resources are sufficient to execute BLOOM. The Company expects average cash use of approximately $1 million per month during study execution, inclusive of BLOOM-related expenditures. As of June 30, 2026, Lipocine reported $23.3 million in unrestricted cash, cash equivalents and marketable investment securities. These expectations are dependent upon study duration, enrollment, costs and other operating requirements and do not imply that existing resources will fund regulatory approval or commercialization.

About the BLOOM Study

The Brexanolone Lifting Outcomes of Moms (BLOOM) study is expected to enroll approximately 120 participants with PPD. It builds on the Company's prior Phase 3 trial (NCT06979544) and incorporates the following design and operational measures:

• Consistent treatment regimen and endpoint: The outpatient study will use the same 48-hour dosing regimen evaluated in the prior Phase 3 trial with primary efficacy, change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score, assessed at 60 hours post dosing initiation.
• Site quality controls: Measures include periodic review of site populations, third-party support for site selection, geographic diversity, with no selection of sites with significant operational or data quality concerns,  and participation by academic sites.
• Measures intended to reduce placebo response: The protocol includes fewer rating scales and assessments, reduced participant contact with site staff, centralized rating for screening and eligibility, and standardized participant eduction about study procedures and assessments.
• Prespecified sensitivity analyses: The study includes planned analyses addressing outlier sites and pharmacokinetic data.

Additional details about BLOOM will be available on ClinicalTrials.gov.

About LPCN 1154

LPCN 1154 (proposed brand name BRLIZIO) is an investigational oral formulation of brexanolone, chemically identical to the naturally occurring neuroactive steroid allopregnanolone, which modulates GABA_A receptors. Lipocine is developing LPCN 1154 as a 48-hour, at-home treatment for PPD, with the goal of rapid relief and a tolerable, practical dosing regimen. LPCN 1154 is not FDA-approved. Its efficacy, safety, suitability for at-home use and any monitoring or activity restrictions remains subject to clinical evaluation and regulatory review. No head-to-head trials have established superiority to approved PPD treatments.

About Postpartum Depression

Postpartum depression is a serious, potentially life-threatening condition that can impair daily functioning, maternal-infant bonding and family well-being. Symptoms may include persistent sadness, loss of interest, anxiety and thoughts of self-harm. CDC research found that approximately 1 in 8 women with a recent live birth reported postpartum depressive symptoms. Treatment options include psychotherapy and antidepressants; zuranolone (ZURZUVAE) is FDA-approved for adults with PPD as a 14-day oral course. Its label includes a boxed warning for driving impairment and advises avoiding driving for at least 12 hours after each dose. IV brexanolone (ZULRESSO) was discontinued commercially in the United States, and FDA approval was withdrawn at the sponsor's request effective April 14, 2025. ACOG's updated guidance, published online in 2025 and in its January 2026 journal issue, addresses neuroactive steroid treatment in the postpartum period. There remains a need for additional effective, well-tolerated, accessible treatments that provide timely relief while fitting the practical demands of caring for a newborn.

About Lipocine

Lipocine is a biopharmaceutical company developing oral therapeutics using its proprietary drug-delivery technology platform. The Company advances product candidates addressing significant unmet medical needs and explores partnerships to support their development and commercialization.

Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of our products and product candidates and related efforts with the FDA, including the design, planned enrollment, timing and potential outcomes of the BLOOM study; the sufficiency of existing financial and operational resources to execute the study; expected average monthly cash use, study expenditures and cash needs; the timing of clinical trials and regulatory submissions, the potential uses and benefits of our products and product candidates, the commercial potential for our product candidates, and potential strategic partnerships and other opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of an NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, variability in enrollment and site performance, study costs exceeding current estimates, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-for-postpartum-depression-302876766.html

SOURCE Lipocine Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the design and goal of the BLOOM Phase 3 study for LPCN 1154?

BLOOM is a placebo-controlled outpatient Phase 3 study of LPCN 1154 in severe postpartum depression. It is intended to complement the existing LPCN 1154 clinical data package and generate prospective efficacy and safety evidence to support a potential New Drug Application under the 505(b)(2) pathway. The study design incorporates feedback from a recent meeting with the U.S. FDA and learnings from the prior Phase 3 trial, including strengthened site and data-quality controls.

How is LPCN 1154 intended to be used for postpartum depression if approved?

LPCN 1154 is being developed as an oral brexanolone regimen designed as a 48-hour, at-home treatment. The company believes this profile could address the need for rapid symptom relief with a short oral course and could represent a commercial opportunity in postpartum depression, subject to successful development and regulatory approval.

What issues were observed at the anomalous site in the prior Phase 3 trial?

In exploratory post hoc analyses of the prior Phase 3 trial, anomalies were concentrated at one high-enrolling site, including an absence of detectable study drug in blood samples from approximately 40% of LPCN 1154-treated participants at that site. When this site was excluded, analyses suggested rapid and sustained improvement in depressive symptoms, but these findings are described as exploratory and not confirmatory evidence of efficacy.

What safety profile did LPCN 1154 show in the prior Phase 3 trial?

The prior Phase 3 trial reported no treatment-related severe or serious adverse events, and there were no instances of excessive sedation, loss of consciousness or treatment discontinuation attributed to treatment. These findings are described as encouraging for safety and tolerability.

How does Lipocine describe its financial capacity to support the BLOOM study?

Based on its current operating plan, Lipocine believes its existing financial and operational resources are sufficient to execute BLOOM. The company expects average cash use of approximately $1 million per month during study execution, inclusive of BLOOM-related expenditures, and reported $23.3 million in unrestricted cash, cash equivalents and marketable investment securities as of June 30, 2026. These expectations depend on factors such as study duration, enrollment, costs and other operating requirements and do not imply funding for regulatory approval or commercialization.